AveXis Priced, Nasdaq: AVXS

Early-stage biotech developing gene therapy for spinal muscular atrophy.

Industry: Health Care

Latest Trade: $75.20 0.00 (0.0%)

First Day Return: -9.8%

Return from IPO: +276.0%

Industry: Health Care

We are a clinical-stage gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in a Phase 1 clinical trial for the treatment of spinal muscular atrophy Type 1, the leading genetic cause of infant mortality. SMA Type 1 is a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, resulting in mortality or the need for permanent ventilation support before the age of two for greater than 90% of patients. The survival motor neuron, or SMN, is a critical protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted, which prevents them from producing adequate levels of functional SMN protein. AVXS-101 is designed to deliver a fully functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels and we believe this will result in improved motor neuron function and patient outcomes.
more less
IPO News for AveXis
more
IPO Data
IPO File Date 01/15/2016
Offer Price $20.00
Price Range $19.00 - $21.00
Offer Shares (mm) 4.8
Deal Size ($mm) $95
IPO Data
IPO Date 02/10/2016
Offer Price $20.00
Price Range $19.00 - $21.00
Offer Shares (mm) 4.8
Deal Size ($mm) $95
Underwriters
more
Company Data
Headquarters Bannockburn, IL
Founded 2010
Employees 18
Website www.avexis.com